Zenas BioPharma (NASDAQ:ZBIO) Announces Earnings Results, Misses Estimates By $3.32 EPS

Zenas BioPharma (NASDAQ:ZBIO) posted its quarterly earnings results on Monday. The company reported ($4.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32), FiscalAI reports.

Zenas BioPharma Stock Down 3.4%

Zenas BioPharma stock opened at $23.23 on Tuesday. The company’s 50-day moving average price is $22.61 and its two-hundred day moving average price is $27.12. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37. The stock has a market cap of $1.25 billion, a P/E ratio of -3.29 and a beta of -1.96. Zenas BioPharma has a twelve month low of $6.11 and a twelve month high of $44.60.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Wall Street Zen raised Zenas BioPharma from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. HC Wainwright reissued a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a report on Tuesday. Evercore assumed coverage on Zenas BioPharma in a research note on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price target on the stock. Morgan Stanley raised their price target on Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Tuesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price objective on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $43.17.

Zenas BioPharma News Roundup

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company secured up to $250 million in non-dilutive, multi‑tranche debt financing from Pharmakon to support development and commercialization plans—improves near-term liquidity and reduces immediate dilution risk. Zenas BioPharma Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Regulatory milestones: Zenas expects to file obexelimab marketing applications for IgG4‑RD with the FDA in Q2 2026 and with the EMA in H2 2026; SunStone SLE topline is due Q4 2026 — these near‑term milestones can materially re‑rate the stock if positive. Zenas BioPharma Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Insider and institutional buying highlighted in recent data (multiple insiders and funds increased stakes), which can signal confidence from management and large holders. Quiver Quant — Inducement Grants (also shows insider activity)
• Neutral Sentiment: Morgan Stanley analyst Judah Frommer maintained a Hold and raised the price target to $21 — the raise is supportive, but the PT remains below some prior analyst targets and near current trading levels, signaling mixed analyst sentiment. TipRanks — Morgan Stanley Rating
• Neutral Sentiment: Company granted inducement stock options (235,700 options at $23.23 and 33,450 RSUs) to new hires to aid recruitment; standard for growth-stage biotech but adds potential future dilution as awards vest. GlobeNewswire — Inducement Grants
• Negative Sentiment: Quarterly GAAP EPS missed heavily: Zenas reported a loss of $4.54 per share vs. consensus roughly -$1.22 — the magnitude of the miss drove investor concern about execution and near‑term profitability. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action expands legal risk and potential financial/operational uncertainty for the company. TipRanks — IPO-Related Securities Class Action

Insider Transactions at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. purchased 57,000 shares of Zenas BioPharma stock in a transaction that occurred on Monday, February 2nd. The stock was acquired at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the purchase, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at $7,599,863.80. This trade represents a 15.57% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Patricia L. Allen acquired 4,160 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was purchased at an average cost of $26.36 per share, for a total transaction of $109,657.60. Following the completion of the acquisition, the director owned 19,860 shares in the company, valued at approximately $523,509.60. This represents a 26.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 202,845 shares of company stock worth $3,747,185 over the last quarter. Company insiders own 16.50% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

A number of hedge funds and other institutional investors have recently modified their holdings of ZBIO. Quarry LP boosted its position in shares of Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the period. Russell Investments Group Ltd. bought a new position in Zenas BioPharma during the third quarter worth about $30,000. BNP Paribas Financial Markets increased its position in Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after acquiring an additional 1,716 shares during the period. Sei Investments Co. acquired a new stake in Zenas BioPharma in the 2nd quarter worth about $118,000. Finally, Bank of America Corp DE raised its stake in Zenas BioPharma by 32.3% in the 2nd quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after purchasing an additional 3,412 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.